Results 221 to 230 of about 137,616 (341)
The liver–gut microbiota axis modulates hepatotoxicity of tacrine in the rat
Lian Yee Yip +14 more
semanticscholar +1 more source
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin +8 more
wiley +1 more source
ABSTRACT A plethora of cellular signaling pathways are dysregulated in cancer cells, promoting carcinogenesis and migration. Cholesterol has recently been linked to cancer by several subcellular mechanisms, especially by its involvement in the formation of lipid rafts, which promote oncogenic signaling and cancer cell invasion. Squalene synthase (SQS),
Danai Mavridi +2 more
wiley +1 more source
Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment. [PDF]
Ashaye A +8 more
europepmc +1 more source
Hepatotoxic Effects of Lithocholic Acid and Sulfolithocholic Acid in Rabbits
Keizo Nakao +4 more
openalex +2 more sources
Exploring Autophagy Inducing Molecules: Targeting Diverse Pathways in Alzheimer's Disease Management
ABSTRACT Neurodegenerative disorders, including Alzheimer's disease (AD), impose a significant burden on society due to their progressive nature and the associated healthcare costs. Autophagy, a vital cellular degradation process, has emerged as a promising therapeutic target in these disorders.
Baljinder Singh +4 more
wiley +1 more source
Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review. [PDF]
Yuan F +5 more
europepmc +1 more source
Tenosynovial Giant Cell Tumor Treatment Revolution: Vimseltinib's Edge Over Pexidartinib
This paper compares vimseltinib and pexidartinib in treating TGCT, highlighting key differences in their efficacy and safety, with vimseltinib showing better tumor reduction. Vimseltinib is more selective for CSF1R, leading to fewer side effects and no liver toxicity, whereas pexidartinib carries a higher risk of hepatotoxicity.
Muhammad Affan Abid +2 more
wiley +1 more source
Comprehensive Evaluation of Hepatotoxicity Following Radiation Therapy in Breast Cancer Patients. [PDF]
Song JY +4 more
europepmc +1 more source

